Alivus Life Sciences Ltd

NSE: ALIVUS · BSE: 543322 · Pharmaceuticals & Biotechnology · 23 announcements

Share price: ₹1,384.70
Market cap: ₹17,000 Cr
Revenue (annual): ₹2,552 Cr
Net profit (annual): ₹564.5 Cr
P/E (TTM): 28.2×Sector 47.4×
Promoter holding: 74.87%+0.00% QoQ
FII holding: 5.54%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Earnings Call 5 Financial Results 4 Results Update 2 Merger & Restructuring 2 Employee Stock Options 2 Board Meeting Date 2 Annual General Meeting 2 Other Announcement 1 Debt & Borrowing 1 Business Update 1 Annual Report 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

1 announcement with these filters

29 Apr 2026 17:09 IST BSE

Debt & Borrowing

Alivus Life Sciences Debt & Borrowing

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) confirmed it is not identified as a Large Corporate for the financial year. The company reported zero outstanding borrowings as of March 31, 2026, and is therefore not required to submit incremental debt disclosures under SEBI's framework.

Read the filing ↗